| Theme |
Chronic kidney disease-mineral and bone disorder (CKD-MBD) guidelines: Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) 2017 CKD-MBD Guidelines Update |
| Title |
Evaluation and treatment of mineral-bone disorder in kidney transplant recipients |
| Author |
Maho Terashita |
Department of Nephrology and Hypertension, St. Marianna University School of Medicine |
| Author |
Masahiko Yazawa |
Department of Nephrology and Hypertension, St. Marianna University School of Medicine |
| Author |
Yugo Shibagaki |
Department of Nephrology and Hypertension, St. Marianna University School of Medicine |
| [ Summary ] |
Advances in immunosuppressive therapy and transplant procedures have improved allograft and patient survival rates, although post-transplant mortality rates remain high as compared to the general population due to the development of cardiovascular events. CKD-MBD is associated with not only fractures, but also cardiovascular events and increased mortality in kidney transplant patients. CKD-MBD in kidney transplant patients is markedly different from that observed in patients with CKD and end-stage kidney disease. It is influenced by several factors such as allograft function, hypophosphatemia, disturbances in the fibroblastic growth factor 23 (FGF-23)-PTH-vitamin D axis, and immunosuppressants. Thus, regular evaluation and better management of CKD-MBD should be conducted after kidney transplantation. |